CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders.

“Following the successful passing of all the proposals at yesterday’s Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million,” said Dr. Andrew Regan, Chief Executive Officer. “Utilizing cutting edge AI and an algorithmic approach, CDT can complete analysis on more than 3,000 diseases in a matter of hours, that might conventionally have taken pharma companies up to 5 years. It’s a breakthrough in drug re-purposing that uniquely positions the Company through a novel approach, which combined with CDT’s focus on developing IP is expected to revolutionize the approach of pharmaceutical companies. CDT Equity is now moving to a phase of out-license deals with disease specific partners and funds.”

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.